COST-EFFECTIVENESS OF PRIMARY PROPHYLAXIS WITH PEGFILGRASTIM VERSUS FILGRASTIM FOR THE PREVENTION OF FEBRILE NEUTROPENIA IN NON-HODGKIN LYMPHOMA AND STAGE II BREAST CANCER PATIENTS IN GERMANY

被引：0
|
作者：
Taylor, D. C. [1 ]
Ozer-Deniz, S. [1 ]
Hill, G. [1 ]
Skornicki, M. [1 ]
Danel, A. [2 ]
Kunz, E. [3 ]
机构：
[1] I3 Innovus, Medford, MA USA
[2] Amgen Europe GmbH, Zug, Switzerland
[3] Amgen Europe GmbH, Munich, Germany
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(11)71963-5
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A263 / A264
页数：2
相关论文
共 50 条
  • [31] Cost-effectiveness of primary prophylaxis with pegfilgrastim in early-stage breast cancer patients receiving chemotherapy in China
    Xia, Wen
    Wang, Shusen
    Hu, Hao
    Xu, Fei
    Jiang, Kuikui
    Yuan, Zhongyu
    Shi, Yanxia
    Zhao, Kun
    Huang, Jia Jia
    Xue, Cong
    Bi, Xiwen
    Lu, Qianyi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [32] Pegfilgrastim for primary prophylaxis of febrile neutropenia in breast cancer patients undergoing TAC chemotherapy
    Lee, Jihyoun
    Lee, Jong Eun
    Kim, Zisun
    Han, Sun Wook
    Hur, Sung Mo
    Kim, Sung Yong
    Lee, Min Hyuk
    Lim, Cheol Wan
    ANNALS OF SURGICAL TREATMENT AND RESEARCH, 2018, 94 (05) : 223 - 228
  • [33] Cost-Effectiveness of Primary versus Secondary Prophylaxis with Pegfilgrastim in Women with Early-Stage Breast Cancer Receiving Chemotherapy
    Ramsey, Scott D.
    Liu, Zhimei
    Boer, Rob
    Sullivan, Sean D.
    Malin, Jennifer
    Doan, Quan V.
    Dubois, Robert W.
    Lyman, Gary H.
    VALUE IN HEALTH, 2009, 12 (02) : 217 - 225
  • [34] Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma-a cost-effectiveness analysis
    Numnum, T. M.
    Kimball, K. J.
    Rocconi, R. P.
    Kilgore, L. C.
    Straughn, J. M., Jr.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2007, 17 (05) : 1019 - 1024
  • [35] Cost-effectiveness of filgrastim-sndz as primary prophylaxis (PP) versus secondary prophylaxis (SP) to prevent chemotherapy-induced febrile neutropenia (FN) in breast cancer patients at intermediate risk.
    Li, Edward C.
    Mezzio, Dylan
    Campbell, Kimberley J.
    Spargo, Andrew
    Lyman, Gary H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (29)
  • [36] Cost-effectiveness of pegfilgrastim vs. filgrastim primary prophylaxis in patients with non-Hodgkins lymphoma receiving CHOP-21 in France
    Maloisel, F.
    Bogillot, O.
    Malin, J.
    Tochon, V.
    Liu, Z.
    Doan, Q.
    Lalla, A.
    Dubois, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 229 - 229
  • [37] Pegfilgrastim primary prophylaxis in patients with non-Hodgkin lymphoma: results from an integrated analysis
    Pettengell, R.
    Schwenkglenks, M.
    Bacon, P.
    Lawrinson, S.
    Duehrsen, U.
    HEMATOLOGICAL ONCOLOGY, 2011, 29 (04) : 177 - 184
  • [38] Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study
    M. Brito
    S. Esteves
    R. André
    M. Isidoro
    A. Moreira
    Supportive Care in Cancer, 2016, 24 : 597 - 603
  • [39] Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study
    Brito, M.
    Esteves, S.
    Andre, R.
    Isidoro, M.
    Moreira, A.
    SUPPORTIVE CARE IN CANCER, 2016, 24 (02) : 597 - 603
  • [40] COST-EFFECTIVENESS ANA LYSIS OF GRANULOCYTE COLONY-STIMULATING FACTORS FOR THE PROPHYLAXIS OF CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA IN GREECE
    Gourzoulidis, G.
    Kourlaba, G.
    Apostolidis, J.
    Lyman, G. H.
    Villa, G.
    Papagiannopoulou, V
    Tritaki, G.
    Maniadakis, N.
    VALUE IN HEALTH, 2015, 18 (07) : A457 - A457
12345